Research Analysts Offer Predictions for AXSM FY2027 Earnings

Key Points

• William Blair raised Axsome Therapeutics' FY2027 earnings per share (EPS) estimate from $11.65 to $11.91, indicating positive expectations for the company's financial performance.
• The consensus estimate for Axsome's current full-year earnings is a loss of -$2.79 per share, contrasting significantly with William Blair's future EPS forecasts.
• A number of analysts have shown confidence in Axsome Therapeutics, with the stock holding an average rating of "Buy" and a target price of $172.33.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at William Blair boosted their FY2027 earnings estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Monday, August 4th. William Blair analyst M. Minter now forecasts that the company will post earnings of $11.91 per share for the year, up from their previous forecast of $11.65. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics' FY2028 earnings at $23.69 EPS and FY2029 earnings at $37.21 EPS.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.08. The firm had revenue of $150.04 million for the quarter, compared to analyst estimates of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%.

Several other brokerages also recently commented on AXSM. Needham & Company LLC restated a "buy" rating and issued a $150.00 target price on shares of Axsome Therapeutics in a research note on Monday, August 4th. Royal Bank Of Canada upped their price target on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the stock an "outperform" rating in a research report on Tuesday. Oppenheimer began coverage on shares of Axsome Therapeutics in a research report on Tuesday, June 3rd. They set an "outperform" rating and a $185.00 price target on the stock. Robert W. Baird upped their price target on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 6th. Finally, Morgan Stanley began coverage on shares of Axsome Therapeutics in a research report on Thursday, July 3rd. They set an "overweight" rating and a $190.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $178.00.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM traded up $0.48 on Tuesday, hitting $104.80. The stock had a trading volume of 311,364 shares, compared to its average volume of 686,543. Axsome Therapeutics has a twelve month low of $75.56 and a twelve month high of $139.13. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.96 and a current ratio of 1.57. The firm's 50 day moving average price is $105.86 and its 200-day moving average price is $110.79. The company has a market capitalization of $5.23 billion, a price-to-earnings ratio of -20.67 and a beta of 0.51.

Insider Buying and Selling

In related news, Director Mark Coleman sold 3,750 shares of the stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $105.47, for a total transaction of $395,512.50. Following the completion of the sale, the director directly owned 50,387 shares of the company's stock, valued at approximately $5,314,316.89. This represents a 6.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Hunter R. Murdock sold 6,014 shares of the firm's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $100.12, for a total transaction of $602,121.68. The disclosure for this sale can be found here. In the last three months, insiders sold 93,437 shares of company stock valued at $9,834,215. 22.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently made changes to their positions in AXSM. Assenagon Asset Management S.A. boosted its holdings in shares of Axsome Therapeutics by 16,852.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company's stock valued at $73,176,000 after buying an additional 623,717 shares during the last quarter. Boxer Capital Management LLC acquired a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $39,767,000. Lazard Asset Management LLC lifted its holdings in Axsome Therapeutics by 525.7% during the 4th quarter. Lazard Asset Management LLC now owns 537,669 shares of the company's stock valued at $45,492,000 after purchasing an additional 451,737 shares during the last quarter. Nuveen LLC acquired a new stake in Axsome Therapeutics during the 1st quarter valued at $48,185,000. Finally, 1832 Asset Management L.P. acquired a new stake in Axsome Therapeutics during the 1st quarter valued at $42,360,000. Institutional investors and hedge funds own 81.49% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.